SNDX SYNDAX PHARMACEUTICALS

Syndax Announces Participation in June Investor Conferences

Syndax Announces Participation in June Investor Conferences

NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:

  • Jefferies Global Healthcare Conference with a fireside chat on Thursday, June 5, 2025, at 1:25 p.m. ET.
  • Goldman Sachs 46th Annual Global Healthcare Conference with a fireside chat on Wednesday, June 11, 2025, at 2:00 p.m. ET.

A live webcast of the fireside chats will be available in the Investor section of the Company's website at , where a replay will also be available for a limited time.

About Syndax

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit or follow the Company on and .

Syndax Contacts

Sharon Klahre

Syndax Pharmaceuticals, Inc.



Tel 781.684.9827

SNDX-G



EN
29/05/2025

Underlying

SNDXSYNDAX PHARMACEUTICALS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SYNDAX PHARMACEUTICALS

 PRESS RELEASE
Free
SNDX SYNDAX PHARMACE...

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing ...

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: ), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on August 1, 2025 the Company granted inducement awards to purchase up to 48,600 shares of common stock to seven new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48...

August 6, 2025 1 EN
 PRESS RELEASE
Free
SNDX SYNDAX PHARMACE...

Syndax Reports Second Quarter 2025 Financial Results and Provides Busi...

Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update – $28.6 million of Revuforj® (revumenib) net revenue, representing 43% growth over 1Q25 – – $36.2 million of Niktimvo™ (axatilimab-csfr) net revenue reported by Incyte in first full quarter of launch; $9.4 million in collaboration revenue reported by Syndax – – sNDA in R/R mNPM1 AML granted Priority Review; PDUFA action date of October 25, 2025 – – $517.9 million in cash, cash equivalents and investments expected to fund the company to profitability – – Company to host a conference call today at 4:30 p.m. ...

August 4, 2025 1 EN
 PRESS RELEASE
Free
SNDX SYNDAX PHARMACE...

Syndax to Announce Second Quarter 2025 Financial Results and Host Conf...

Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025 NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its second quarter 2025 financial results and provide a business update on Monday, August 4, 2025. In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Monday, August 4, 2025. The live audio webcast a...

July 28, 2025 1 EN
 PRESS RELEASE
Free
SNDX SYNDAX PHARMACE...

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing ...

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: ), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on July 1, 2025 the Company granted inducement awards to purchase up to 228,400 shares of common stock to 14 new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th o...

July 2, 2025 1 EN
 PRESS RELEASE
Free
SNDX SYNDAX PHARMACE...

Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib)...

Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia – PDUFA action date set for October 25, 2025 – – sNDA being reviewed under FDA’s RTOR program – – Revumenib has the potential to become the first and only menin inhibitor approved in both R/R mNPM1 AML and R/R KMT2Ar acute leukemia – NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the U.S. Food and Drug Administration...

June 24, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch